Novartis raised peak sales forecasts for three major drugs to $18 billion, up from $14 billion previously. The Swiss pharma company now projects Kesimpta, Scemblix, and Leqvio will reach that combined peak, driven by strong commercial performance, growing market share, and robust U.S. and Asia demand, CEO Vas Narasimhan said.

The company revised annual sales growth guidance to 5% through 2031, down slightly from prior guidance of 5% to 6% through 2030. Narasimhan attributed the more cautious outlook to expected U.S. generic competition for breast cancer drug Kisqali entering in the second half of 2031.

Novartis shares fell 2.4% in mid-morning Swiss trading. Citi analysts said the 2031 sales guidance ran about 3% above consensus but noted the market remained skeptical of post-2031 growth pending additional pipeline data.

Narasimhan defended Novartis' capital allocation strategy following recent setbacks. The company faced a failed cardiovascular pelacarsen trial in September and a failed late-stage trial for del-desiran, which Novartis acquired through a $12 billion Avidity Biosciences deal. Narasimhan cited a 275% total shareholder return over the past decade as evidence the strategy ranked among sector top performers.

Investors watching Novartis (NOVN) should monitor whether Kesimpta, Scemblix, and Leqvio growth outpaces patent cliff losses and whether pipeline programs can sustain sales momentum beyond 2031.